| HOME >> BIOLOGY >> TECHNOLOGY |
About Baxter's GAMMAGARD LIQUID(TM) 10%
GAMMAGARD LIQUID 10% (known as KIOVIG(TM) in Europe) is indicated for the treatment of primary immunodeficiency disorders associated with defects in immune system. These include but are not limited to congenital X-linked agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.
Important Safety Information for the United States
GAMMAGARD LIQUID 10% is contraindicated in patients with known anaphylactic or severe hypersensitivity responses to Immune Globulin (Human). Patients with severe selective IgA deficiency (IgA < 0.05 g/L) may develop anti-IgA antibodies that can result in a severe anaphylactic reaction.
Immune Globulin Intravenous (Human) products have been reported to be
associated with renal dysfunction, acute renal failure, osmotic nephrosis,
and death. Patients predisposed to acute renal failure include patients
with any degree of pre-existing renal insufficiency, diabetes mellitus, age
greater than 65, volume depletion, sepsis, paraproteinemia, or patients
receiving known nephrotoxic drugs. Especially in such patients, IGIV
products should be administered at the minimum concentration available and
th
'/>"/>
| SOURCE Baxter International Inc. Copyright©2007 PR Newswire. All rights reserved |